行情

SPHS

SPHS

Sophiris Bio
NASDAQ

实时行情|Nasdaq Last Sale

0.6555
+0.0141
+2.20%
已收盘, 16:00 09/23 EDT
开盘
0.6414
昨收
0.6414
最高
0.6913
最低
0.6200
成交量
19.05万
成交额
--
52周最高
2.950
52周最低
0.6200
市值
2,200.65万
市盈率(TTM)
-10.5897
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

SPHS 新闻

  • Stocks That Hit 52-Week Lows On Monday
  • Benzinga.2小时前
  • The Daily Biotech Pulse: FDA Approves Merck HIV Drugs, Five Prime CEO Quits, HTG Molecular Announces Secondary Offering
  • Benzinga.3天前
  • The Daily Biotech Pulse: China Biologics Receives Buyout Offer, Provention Bio Offering, Exagen IPO
  • Benzinga.4天前
  • Sophiris Bio (SPHS) Investor Presentation - Slideshow
  • Seeking Alpha - Article.09/16 16:47

更多

所属板块

制药
-0.35%
制药与医学研究
-0.43%

热门股票

名称
价格
涨跌幅

SPHS 简况

Sophiris Bio Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing products for the treatment of urological diseases. The Company is developing topsalysin (PRX302) as a treatment for the lower urinary tract symptoms of benign prostatic hyperplasia (BPH) commonly referred to as an enlarged prostate and as a treatment for localized low to intermediate risk prostate cancer. Topsalysin, a genetically modified recombinant protein, is delivered through ultrasound-guided injection directly into the prostate. This membrane-disrupting protein is selectively activated by enzymatically active prostate specific antigen (PSA), which is only present in the prostate, leading to localized cell death and tissue disruption without damage to neighboring tissue and nerves. This method of administration limits the circulation of the drug in the body. The Company has completed Phase III clinical trials of topsalysin.
展开

Webull提供Sophiris Bio Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。